100 related articles for article (PubMed ID: 16357508)
1. Tumor-targeted therapy with a conditionally replicating mutant of HSV-1 induces regression of xenografted human hepatomas.
Xue F; Dong CY; Su Y; Zhu H; Ling W; Liu Y; Xu H; Xiao W; Zhou S; Qi YP
Cancer Biol Ther; 2005 Nov; 4(11):1234-9. PubMed ID: 16357508
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene, icp34.5.
Lan P; Dong C; Qi Y; Xiao G; Xue F
J Biochem Mol Biol; 2003 Jul; 36(4):379-86. PubMed ID: 12895296
[TBL] [Abstract][Full Text] [Related]
3. Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice.
Zhu H; Su Y; Zhou S; Xiao W; Ling W; Hu B; Liu Y; Qi Y
Cancer Biol Ther; 2007 May; 6(5):724-31. PubMed ID: 17592250
[TBL] [Abstract][Full Text] [Related]
4. Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft.
Santamaría E; Mora MI; Carro-Roldán E; Molina M; Fernández-Irigoyen J; Marconi P; Manservigi R; Greco A; Epstein AL; Prieto J; Hernández-Alcoceba R; Corrales FJ
J Proteomics; 2009 Nov; 73(1):153-60. PubMed ID: 19540947
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
6. Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3.
Su Y; Zhu H; Xiao W; Xu Q; Zhu L; Zhang X; Wan Q; Zhou S; Du E; Xu H; Yao L; Lv S; Hu B; Liu Y; Qi Y
Cancer Biol Ther; 2007 Feb; 6(2):202-8. PubMed ID: 17218780
[TBL] [Abstract][Full Text] [Related]
7. Rasgrp2 regulates the permissiveness of NIH3T3 cells to a herpes simplex virus 1 mutant with inactivated ICP34.5 gene.
Xiao W; Su Y; Zhou S; Yi Ch; He G; Liu Y; Qi Y
Acta Virol; 2013; 57(1):41-9. PubMed ID: 23530823
[TBL] [Abstract][Full Text] [Related]
8. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy using tissue-specific replication competent HSV.
Miyatake S
Hum Cell; 2002 Sep; 15(3):130-7. PubMed ID: 12703543
[TBL] [Abstract][Full Text] [Related]
11. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
14. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.
Dai M; Liu J; Chen DE; Rao Y; Tang ZJ; Ho WZ; Dong CY
Cancer Gene Ther; 2012 Feb; 19(2):77-83. PubMed ID: 21959967
[TBL] [Abstract][Full Text] [Related]
17. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
18. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
19. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
